Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
11 Results for "
CDK9-IN-2
" in MedChemExpress (MCE) Product Catalog:
Products (11)
11 Results for "CDK9-IN-2" in MCE Product Catalog:
7
7 Cited Publications
Cat. No.: HY-16462
CAS No.: 1263369-28-3
CDK9-IN-2 is a special cyclin-dependent kinase 9 (CDK9) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC50 of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively.
Cat. No.: HY-112811
CAS No.: 2435721-30-3
PROTAC CDK9 degrader-2 is a PROTAC degrader targeting CDK9, with an IC50 of 523 nM. PROTAC CDK9 degrader-2 selectively degrades CDK9 via the cereblon-dependent ubiquitin-proteasome pathway and inhibits the proliferation of cancer cells overexpressing CDK9. PROTAC CDK9 degrader-2 can be used for cancer research .
Cat. No.: HY-176165
CAS No.: 3081246-18-3
Target:
Research Areas:
CDK9/EZH2-IN-1 (Compound D16) is a CDK9/EZH2 dual-target inhibitor (IC50: 83.9/108.6 nM). CDK9/EZH2-IN-1 induces apoptosis and DNA double-strand breaks (DSBs). CDK9/EZH2-IN-1 inhibits the proliferation activity of MKN45, MDA-MB-453 and SW620 cancer cells (IC50 values are 136.3, 171.3 and 315.7 nM, respectively) .
Cat. No.: HY-156083
CAS No.: 3020773-81-0
Target:
Research Areas:
CDK9 degrader-2 is a bifunctional degrader of ATTEC (Autophagy-Tethering Compound) that degrades the CDK9/cyclin T1 complex. CDK9 degrader-2 forms a ternary complex with CDK9 and LC3B, and achieves degradation through the autophagy-lysosome pathway, a process independent of the ubiquitin-proteasome system. CDK9 degrader-2 downregulates the expression of Mcl-1 and c-Myc proteins, induces apoptosis, and exhibits antitumor activity in in vivo MV4-11 xenograft models. CDK9 degrader-2 can be used for leukemia research .
Cat. No.: HY-160235
CAS No.: 2732859-29-7
Research Areas:
Pomalidomide-C2-amide-C5-azidea is an E3 linker conjugate, pomalidomide, that can be used to synthesize highly effective PROTAC molecules towards CDK9. Pomalidomide-C2-amide-C5-azidea has antiproliferative activity .
Cat. No.: HY-189422
CDK9/EZH2-IN-2 is a potent dual CDK9 and EZH2 inhibitor with an IC50 of 8.9 nM against EZH2. CDK9/EZH2-IN-2 inhibits anti-apoptotic proteins and induces DNA damage by blocking the activity of CDK9 and EZH2, ultimately leading to tumor cell apoptosis. CDK9/EZH2-IN-2 can be used for research on diffuse large B-cell lymphoma .
Cat. No.: HY-150946
CAS No.: 1453836-45-7
Research Areas:
CDK9 ligand 2 (compound CDK9 ligand 4) is a CDK9 ligand. CDK9 ligand 2 is used for the synthesis of PROTAC CDK9 degrader-14 (HY-133617) .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
